Page 10«..9101112..2030..»

VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 – Yahoo Finance

By daniellenierenberg

SOUTH SAN FRANCISCO, CA--(Marketwired - March 29, 2017) - VistaGen Therapeutics Inc. (VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the European Patent Office (EPO) has issued a Notice of Intention to Grant the Company's European Patent Application for AV-101, its oral CNS prodrug candidate in Phase 2 development for major depressive disorder (MDD)

To Read More: VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 – Yahoo Finance
categoriaCardiac Stem Cells commentoComments Off on VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 – Yahoo Finance | dataMarch 31st, 2017
Read All

$50 million gift to Packard Children’s Hospital will advance care … – Stanford Medical Center Report

By daniellenierenberg

Next wave of innovation and discovery Over the past 70 years, new surgical techniques and medical therapies, some of which were developed at the Stanford School of Medicine and Packard Childrens, have evolved and greatly improved outcomes for children with almost every type ofcongenital heart disease. Heart defects that were once universally fatal can now be surgically improved. As patients born with heart disease survive longer, there are now more adults than children in the United States with congenital heart disease

To Read More: $50 million gift to Packard Children’s Hospital will advance care … – Stanford Medical Center Report
categoriaCardiac Stem Cells commentoComments Off on $50 million gift to Packard Children’s Hospital will advance care … – Stanford Medical Center Report | dataMarch 29th, 2017
Read All

Researchers turn to the vascular system of plants to solve a major bioengineering problem blocking the regeneration … – Science Daily

By JoanneRUSSELL25

Researchers turn to the vascular system of plants to solve a major bioengineering problem blocking the regeneration ...

To Read More: Researchers turn to the vascular system of plants to solve a major bioengineering problem blocking the regeneration … – Science Daily
categoriaCardiac Stem Cells commentoComments Off on Researchers turn to the vascular system of plants to solve a major bioengineering problem blocking the regeneration … – Science Daily | dataMarch 27th, 2017
Read All

Human heart muscle made from stem cells – Free Press Journal

By Sykes24Tracey

By FPJ Bureau|Mar 20, 2017 06:26 pm Melbourne: Scientists have created a functional beating human heart muscle from stem cells, a significant step forward in cardiac disease research.

To Read More: Human heart muscle made from stem cells – Free Press Journal
categoriaCardiac Stem Cells commentoComments Off on Human heart muscle made from stem cells – Free Press Journal | dataMarch 26th, 2017
Read All

Measuring Heart Toxicity of Cancer Drugs | Technology Networks – Technology Networks

By LizaAVILA

A stem cell-derived heart muscle cell. Proteins that are important for muscle cell contraction are highlighted in red and green, and cell nuclei are blue. Credit: Joseph C

To Read More: Measuring Heart Toxicity of Cancer Drugs | Technology Networks – Technology Networks
categoriaCardiac Stem Cells commentoComments Off on Measuring Heart Toxicity of Cancer Drugs | Technology Networks – Technology Networks | dataMarch 25th, 2017
Read All

Measuring Heart Toxicity of Cancer Drugs – Technology Networks

By admin

A stem cell-derived heart muscle cell. Proteins that are important for muscle cell contraction are highlighted in red and green, and cell nuclei are blue. Credit: Joseph C.

To Read More: Measuring Heart Toxicity of Cancer Drugs – Technology Networks
categoriaCardiac Stem Cells commentoComments Off on Measuring Heart Toxicity of Cancer Drugs – Technology Networks | dataMarch 24th, 2017
Read All

Pathologists and Clinical Laboratories May Soon Have a Test for Identifying Cardiac Patients at Risk from Specific … – DARKDaily.com – Laboratory…

By admin

Published: March 22 2017 Stanford University School of Medicine researchers grew heart muscle cells and used them, along with CRISPR, to predict whether a patient would benefit or experience bad side effects to specific therapeutic drugs What would it mean to pathology groups if they could grow heart cells that mimicked a cardiac patients own cells?

To Read More: Pathologists and Clinical Laboratories May Soon Have a Test for Identifying Cardiac Patients at Risk from Specific … – DARKDaily.com – Laboratory…
categoriaCardiac Stem Cells commentoComments Off on Pathologists and Clinical Laboratories May Soon Have a Test for Identifying Cardiac Patients at Risk from Specific … – DARKDaily.com – Laboratory… | dataMarch 22nd, 2017
Read All

‘Beating’ Heart Created from Stem Cells – Technology Networks

By NEVAGiles23

Scientists at The University of Queensland have taken a significant step forward in cardiac disease research by creating a functional beating human heart muscle from stem cells.

To Read More: ‘Beating’ Heart Created from Stem Cells – Technology Networks
categoriaCardiac Stem Cells commentoComments Off on ‘Beating’ Heart Created from Stem Cells – Technology Networks | dataMarch 22nd, 2017
Read All

Stem Cell Cardiac Toxicity Model for Testing Chemotherapy Agents – Technology Networks

By NEVAGiles23

A team of scientists has developed a new safety index for a common group of chemotherapy drugs, by using a stem cell model to screen such therapies for their potential to damage patients hearts. The study, published in Science Translational Medicine, was co-authored by Paul Burridge, PhD, assistant professor of Pharmacology. Tyrosine kinase inhibitors (TKIs), a class of chemotherapy drugs, have become increasingly important in treating many types of cancer.

To Read More: Stem Cell Cardiac Toxicity Model for Testing Chemotherapy Agents – Technology Networks
categoriaCardiac Stem Cells commentoComments Off on Stem Cell Cardiac Toxicity Model for Testing Chemotherapy Agents – Technology Networks | dataMarch 22nd, 2017
Read All

TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction – GlobeNewswire (press release)

By admin

March 13, 2017 02:00 ET | Source: TiGenix NV multilang-release PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction Leuven (BELGIUM) - March 13, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derived stem cells (eASC) and donor-derived expanded cardiac stem cells (AlloCSCs), today announced top-line one-year results from the CAREMI clinical trial, an exploratory Phase I/II study of AlloCSCs in acute myocardial infarction (AMI). CAREMI is the first-in-human clinical trial with the primary objective being safety and evaluating the feasibility of an intracoronary infusion of 35 million of AlloCSCs in patients with AMI and left ventricular dysfunction treated within the first week post-AMI.

To Read More: TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction – GlobeNewswire (press release)
categoriaCardiac Stem Cells commentoComments Off on TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction – GlobeNewswire (press release) | dataMarch 19th, 2017
Read All

Self-repairing heart tissue breakthrough brings hope for cardiac … – ABC Online

By Sykes24Tracey

Updated March 17, 2017 13:31:00 Queensland researchers have used stem cells to create a beating human heart muscle, as well as heart tissue that is able to repair itself. Doctors James Hudson and Enzo Porello from the University of Queensland worked with German researchers to create the samples in a laboratory, and will use them to study cardiac biology and diseases.

To Read More: Self-repairing heart tissue breakthrough brings hope for cardiac … – ABC Online
categoriaCardiac Stem Cells commentoComments Off on Self-repairing heart tissue breakthrough brings hope for cardiac … – ABC Online | dataMarch 18th, 2017
Read All

Belgium’s Tigenix says heart attack stem cell trial successful – Reuters

By JoanneRUSSELL25

BRUSSELS Belgian biotech group Tigenix said on Monday its medical trial with a novel treatment for patients at risk of heart failure after a coronary attack was successful. The group said patients treated in its PhaseI/II trial of donor-derived expanded cardiac stem cells (AlloCSC) showed no side-effects and all of them continued to live after 30 days, six months and a year. Tigenix added that in one subgroup of trial patients associated with a poor long-term outlook, there was a larger reduction in the size of infarction, tissue death due to inadequate blood supply

To Read More: Belgium’s Tigenix says heart attack stem cell trial successful – Reuters
categoriaCardiac Stem Cells commentoComments Off on Belgium’s Tigenix says heart attack stem cell trial successful – Reuters | dataMarch 16th, 2017
Read All

Scientists create ‘beating’ human heart muscle for cardiac research – UQ News

By daniellenierenberg

Scientists at The University of Queensland have taken a significant step forward in cardiac disease research by creating a functional beating human heart muscle from stem cells. Dr James Hudson and Dr Enzo Porrello from the UQ School of Biomedical Sciences collaborated with German researchers to create models of human heart tissue in the laboratory so they can study cardiac biology and diseases in a dish.

To Read More: Scientists create ‘beating’ human heart muscle for cardiac research – UQ News
categoriaCardiac Stem Cells commentoComments Off on Scientists create ‘beating’ human heart muscle for cardiac research – UQ News | dataMarch 16th, 2017
Read All

Belgium’s Tigenix says heart attack stem cell trial successful – KFGO

By daniellenierenberg

Monday, March 13, 2017 3 a.m.

To Read More: Belgium’s Tigenix says heart attack stem cell trial successful – KFGO
categoriaCardiac Stem Cells commentoComments Off on Belgium’s Tigenix says heart attack stem cell trial successful – KFGO | dataMarch 15th, 2017
Read All

Woodrose Ventures Corporation Announces Proposed Acquisition … – Marketwired (press release)

By raymumme

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 13, 2017) - NOT FOR DISSEMINATION IN THE UNITED STATES Editors Note: There is a photo associated with this press release. Woodrose Ventures Corporation (TSX VENTURE:WRS.H) ("Woodrose" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") dated March 10, 2017 to acquire all of the shares of Novoheart Holdings Ltd. ("Novoheart"), a global stem cell biotechnology company dedicated to human heart engineering (the "Transaction")

To Read More: Woodrose Ventures Corporation Announces Proposed Acquisition … – Marketwired (press release)
categoriaCardiac Stem Cells commentoComments Off on Woodrose Ventures Corporation Announces Proposed Acquisition … – Marketwired (press release) | dataMarch 14th, 2017
Read All

Daiichi Sankyo forges $12M pact for GPCR pain program with Heptares; Incyte shares jump on latest takeover chatter – Endpoints News

By JoanneRUSSELL25

Heptares struck a $12 million deal to partner with Daiichi Sankyo on a new GPCR pain drug. The UK biotech gets $4 million upfront and $8 million in research support along with an unspecified set of milestones for the deal, in which the Sosei subsidiary will search for new drugs that can be developed for pain.

To Read More: Daiichi Sankyo forges $12M pact for GPCR pain program with Heptares; Incyte shares jump on latest takeover chatter – Endpoints News
categoriaCardiac Stem Cells commentoComments Off on Daiichi Sankyo forges $12M pact for GPCR pain program with Heptares; Incyte shares jump on latest takeover chatter – Endpoints News | dataMarch 14th, 2017
Read All

VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire (press release)

By LizaAVILA

March 10, 2017 15:16 ET | Source: NASDAQ, Inc. ADVISORY, March 10, 2017 (GLOBE NEWSWIRE) -- What:VistaGen Therapeutics Inc. (Nasdaq:VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, will visit the Nasdaq MarketSite in Times Square

To Read More: VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire (press release)
categoriaCardiac Stem Cells commentoComments Off on VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire (press release) | dataMarch 11th, 2017
Read All

Cardiac research nets Holly Mewhort prestigious heart association award – UCalgary News

By NEVAGiles23

Numerous people may say they want to grow up to be a heart surgeon, but very few actually achieve that goal.

To Read More: Cardiac research nets Holly Mewhort prestigious heart association award – UCalgary News
categoriaCardiac Stem Cells commentoComments Off on Cardiac research nets Holly Mewhort prestigious heart association award – UCalgary News | dataMarch 10th, 2017
Read All

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community

By raymumme

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial P&T Community Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate, AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial Infarction (AMI). In addition, the second product candidate from the cardiac stem ... and more »

To Read More: TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community
categoriaCardiac Stem Cells commentoComments Off on TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community | dataMarch 10th, 2017
Read All

Robert Clayton Robbins Top Choice for UA President – Arizona Public Media

By Sykes24Tracey

Robert Clayton Robbins, head of the Texas Medical Center, was named Tuesday as top choice for president of the University of Arizona. The Board of Regents selected Robbins in Phoenix following interviews with him and one other candidate Monday. Robbins will meet the campus community and the public at a forum Wednesday afternoon.

To Read More: Robert Clayton Robbins Top Choice for UA President – Arizona Public Media
categoriaCardiac Stem Cells commentoComments Off on Robert Clayton Robbins Top Choice for UA President – Arizona Public Media | dataMarch 9th, 2017
Read All